Vertex Pharmaceuticals (VRTX) Financial Analysis & Valuation | Quarter Chart
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis trans... more
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializ... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $137.50B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Reshma Kewalramani |
| IPO Date | 1991-07-24 | CAGR | 27.73% |
| Employees | 6,400 | Website | www.vrtx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.74% | Total Yield | 0.74% |
VRTX chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $137.01B | P/E | 28.51 | Forward P/E | 27.19 | PEG | -0.91 |
| P/S | 10.96 | P/B | 6.81 | P/CF | 38.5 | P/FCF | 44.42 |
| Sales | $12.99B | Sales 1Y | 10.79% | Sales 3Y | 34.54% | Sales 5Y | 82.18% |
| EPS | $19.03 | EPS 1Y | 9.59% | EPS 3Y | 16.58% | EPS 5Y | 86.55% |
| Sales QoQ | 3.21% | EPS QoQ | -40.6% | Sales QoQ Avg | 3.07% | EPS QoQ Avg | -9.06% |
| Gross Margin | 85.57% | Operating Margin | 33.87% | Profit Margin | 30.61% | ROCE | 15.86% |
| ROA | 12% | ROE | 20% | Altman Z Score | 8.8 | Piotroski Score | 4 |
| Current Ratio | 2.34 | Quick Ratio | 1.89 | Cash Ratio | 1 | Op. CF Ratio | 0.13 |
| Debt/Equity | 0.31 | Debt/Assets | 0.2 | Lt Debt/Equity | 0.26 | Lt Debt/Cap. | 0.14 |
| Intrst Cov. | 111.93 | Inventory Turnover | 0.83 | Asset Turnover | 0.4 | Receivables Turnover | 5.62 |
| Enterprise Value | $137.01B | P/E Ratio | 28.51 |
| Forward P/E | 27.19 | PEG Ratio | -0.91 |
| P/S Ratio | 10.96 | P/B Ratio | 6.81 |
| P/CF Ratio | 38.5 | P/FCF Ratio | 44.42 |
| EPS | $19.03 | EPS Growth 1Y | 9.59% |
| EPS Growth 3Y | 16.58% | EPS Growth 5Y | 86.55% |
| Revenue Growth 1Y | 10.79% | Gross Margin | 85.57% |
| Operating Margin | 33.87% | Profit Margin | 30.61% |
| ROE | 20% | ROA | 12% |
| ROCE | 15.86% | Current Ratio | 2.34 |
| Quick Ratio | 1.89 | Cash Ratio | 1 |
| Debt/Equity | 0.31 | Interest Coverage | 111.93 |
| Altman Z Score | 8.8 | Piotroski Score | 4 |
Vertex Pharmaceuticals (VRTX) valuation & financials
Vertex Pharmaceuticals (VRTX) has a market capitalization of $137.50B and trades at a price-to-earnings ratio of 28.5. It operates in the Healthcare sector (Biotechnology).
Vertex Pharmaceuticals's revenue grew +10.8% over the last year.
Vertex Pharmaceuticals's next earnings report is scheduled for February 11, 2027 after market close (provider scheduled date); analysts estimate EPS of $4.23. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)